Collaborating to restore vision and improve lives
The eye is one of the most complex organs in the human body. Consequently, ophthalmology studies are highly specialized, requiring intimate knowledge of the patient and caregiver experience, deep relationships with quality research sites as well as technical skills for visual assessment, ocular imaging
and a spectrum of treatment modalities.
Since 2016, Syneos Health has supported the development and commercialization of approximately 50 approved therapies for eye disorders, making us a leading Ophthalmology contract research organization providing development services for drug, device and diagnostics in vision care.
Always starting with the end in mind
At Syneos Health, we partner with a problem solving mindset to provide you with integrated scientific, clinical, regulatory, commercialization and marketing expertise.
We bring commercial insights forward into clinical development with teams that combine traditional functions (i.e., project managers, medical monitors, CRAs, and therapeutic and functional experts) with specialists in market access, study branding and patient engagement/advocacy, medical science liaisons and nurse educators. In fact, within the from 2016 to 2021, we have developed, launched and managed more than 45 ophthalmic brands.
We constantly share insights that lead to better, smarter and more innovative clinical development and commercialization solutions.
Strong and enduring site relationships
Given our deep experience, we have developed long-lasting relationships with ophthalmology investigators at nearly 600 sites around the world—many of whom are members of our exclusive Ophthalmology Catalyst Site Network.
The Network includes a number of elite, high-performing ophthalmology sites from across North America, Europe and Asia-Pacific with a proven track record of meeting or exceeding performance goals. Working with our Catalyst sites, you’ll have access to their clinical and therapeutic expertise, and the opportunity to see higher patient recruitment and enrollment rates, and experience fast study start-ups and quality finishes.
Working with our Catalyst sites, you’ll have access to their clinical and therapeutic expertise, and the opportunity to see higher patient recruitment and enrollment rates, and experience fast study start-ups and quality finishes.
We listen and learn from patients every day
The very nature of ocular disease means patients have reduced quality of life, high reliance on caregivers and, especially for elderly patients, frequent comorbidities. We understand the patient experience and plan supportive services to ease the burden for study subjects and their families. Our Patient Voice Consortium supports our commitment to keeping patients at the center of innovation.